6,225 reports of this reaction
1.8% of all CETIRIZINE HYDROCHLORIDE ALLERGY reports
#11 most reported adverse reaction
GLOSSODYNIA is the #11 most commonly reported adverse reaction for CETIRIZINE HYDROCHLORIDE ALLERGY, manufactured by Aurohealth LLC. There are 6,225 FDA adverse event reports linking CETIRIZINE HYDROCHLORIDE ALLERGY to GLOSSODYNIA. This represents approximately 1.8% of all 341,924 adverse event reports for this drug.
Patients taking CETIRIZINE HYDROCHLORIDE ALLERGY who experience glossodynia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
GLOSSODYNIA is a less commonly reported adverse event for CETIRIZINE HYDROCHLORIDE ALLERGY, but still significant enough to appear in the safety profile.
In addition to glossodynia, the following adverse reactions have been reported for CETIRIZINE HYDROCHLORIDE ALLERGY:
The following drugs have also been linked to glossodynia in FDA adverse event reports:
GLOSSODYNIA has been reported as an adverse event in 6,225 FDA reports for CETIRIZINE HYDROCHLORIDE ALLERGY. This does not prove causation, but indicates an association observed in post-market surveillance data.
GLOSSODYNIA accounts for approximately 1.8% of all adverse event reports for CETIRIZINE HYDROCHLORIDE ALLERGY, making it a notable side effect.
If you experience glossodynia while taking CETIRIZINE HYDROCHLORIDE ALLERGY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.